QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.
Real-world evidence & analytics
Quantify is the leading provider of RWE generated from the world-renouned Nordic data. Through our local presence, expert staff, institutional know-how and more than 10 years’ hands-on experience with the Nordic data, we offer an unparalleled ability to advise and execute Nordic RWE studies with local and global applications. Quantify has a successful track record of advising clients on securing Nordic ethical approval, data access, and optimizing analysis for commercial or regulatory purposes. We also offer RWE services in the EU, UK, and US.
Modelling, Access & Strategy
Quantify is a global provider of health economic evidence and a specialist provider of Nordic market access services including economic models, reimbursement dossiers, and strategic advice. Our experience and expertise ensures an optimized, streamlined market access process across the Nordics. For non-technical stakeholders, Quantify also develops value tools and visualisation dashboards to enhance communication. Our expert staff include ex-payers, ex-pharma,ย modelling experts, and experienced project managers.
Evidence review & synthesis
Quantify has long standing experience reviewing, interpreting and communicating evidence as part of targeted or systematic literature reviews (SLR). Our team ensures these activities are done systematically, with a focus on usability, to support knowledge management and commercialization activities. QUANTIFY is experienced in summarizing the results of this work through meta-analyses and narrative reviews. Our team consists of 50% PhDs and integrated AI solutions to provide our clients with the very best services.
Press
Interested in how the Quantify team can help in meeting post-authorization commitments through Nordic RWE?
The Quantify Research team has years of experience of designing, supporting, and managing post-authorization studies, and has been a proud partner to the European Medicines Agency-coordinated ENCePPย (European Network for Centres of Pharmacoepidemiology and Pharmacovigilance) initiative since 2020.
The Nordic data landscape is uniquely suited for studies on drug utilization, assessments of risk minimization measures, and long-term safety, due to several key factors:
๐๐๐ญ๐ข๐จ๐ง๐๐ฅ ๐๐จ๐ฏ๐๐ซ๐๐ ๐ ๐๐ง๐ [โฆ]
Searching for that Friday feeling?
This week the Quantify Research team started early by going to Golfbaren Sverige for a round of mini golf on Thursday night. โณ
The sun was shining and the competitive spirits ran high!
A big shout out to the winning team, number 3:
Helena Skrรถder Lรถveborn, Marcelina Kฤ
dziela and Hannah Norman
Well played you guys! ? ? ?
๐ข ๐๐ฎ๐๐ง๐ญ๐ข๐๐ฒ ๐ฉ๐ฎ๐๐ฅ๐ข๐ฌ๐ก ๐ ๐ญ๐๐ซ๐ ๐๐ญ ๐ญ๐ซ๐ข๐๐ฅ ๐๐ฆ๐ฎ๐ฅ๐๐ญ๐ข๐จ๐ง ๐ข๐ง ๐๐๐
ย
Target trial emulation constitutes an important conceptual framework for increasing the validity of causal inference in observational pharmacoepidemiologic research and is [โฆ]
Read Quantifyยดs publication assessing recent changes to adult national immunization programs for pneumococcal vaccination
In December 2023, Quantifyโs Stuti Arya, Nicholas Norton and Puneet Kaushik published a study assessing recent changes to adult national immunization programs for pneumococcal vaccination and attempting to determine how those changes impacted coverage in European Adults. The review revealed evidence of a convergence towards immunization programs involving sequential vaccination with a higher-valency conjugate vaccine (PCV) followed by the polysaccharide vaccine (PPV23), with a common aim of reducing economic [โฆ]
